A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
Status:
Not yet recruiting
Trial end date:
2024-01-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the
candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of
glycoproteins B (gB) and pentamer antigens adjuvanted, regardless of baseline CMV
sero-status. This FTiH study will be conducted in healthy adults 18 to 50 years of age, in
which the 4 dose levels of the vaccine will be administered in a step-wise dose escalation
manner, based upon safety adjudication.